8-K: Bowen Acquisition Corp Faces Nasdaq Delisting Amid Non-Compliance

Bowen Acquisition Corp has received a delisting determination from Nasdaq due to failure to meet multiple listing standards, including minimum shareholder count and market value requirements, leading to a trading halt.

Summary

• Bowen Acquisition Corp (BOWN) received a written notice on July 11, 2025, and a delisting determination letter on July 15, 2025, from the Nasdaq Stock Market.
• The company is not in compliance with Nasdaq Listing Rule 5450(a)(2) for failing to maintain a minimum of 400 total shareholders for continued listing.
• Additionally, the company failed to meet Nasdaq Listing Rule 5450(b)(2)(A), which requires a Market Value of Listed Securities of at least $50,000,000 for a period of 30 consecutive trading days.
• The company also did not comply with Nasdaq Listing Rule 5450(b)(2)(B), which mandates a minimum of 1,100,000 Publicly Held Shares.
• Furthermore, the company failed Nasdaq Listing Rule 5450(b)(2)(C), requiring a Market Value of Publicly Held Shares of at least $15,000,000 for a period of 30 consecutive trading days.
• Nasdaq is applying more stringent criteria as permitted under Listing Rule 5101 and determined to halt trading in BOWN's securities on July 15, 2025.
• BOWN intends to appeal the delisting determinations to a Nasdaq Hearings Panel and request a stay of the suspension of its securities from trading.
• Unless an appeal is requested by July 22, 2025, at 4:00 p.m. Eastern Time, trading of BOWN's securities will be suspended at the opening of business on July 24, 2025, and Nasdaq will file a Form 25-NSE with the SEC to remove the securities from listing.
• The company is diligently attempting to consummate its previously announced business combination with Shenzhen Qianzhi BioTechnology Co. Ltd., believing that it will be in compliance with listing requirements upon consummation of such transaction.

Sentiment

Score: 2

Explanation: The company faces imminent delisting from Nasdaq and its securities have been halted, indicating severe non-compliance with multiple listing standards. While management intends to appeal and believes a merger will resolve issues, there are no assurances, making the outlook highly negative.

Positives

• The company intends to appeal Nasdaq's delisting determination to a Nasdaq Hearings Panel.
• The company plans to request a stay of the suspension of its securities from trading.
• The company believes it will regain compliance with listing requirements upon consummation of its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.

Negatives

• Received a delisting determination from Nasdaq for failing to meet multiple listing standards.
• Failed to maintain a minimum of 400 total shareholders.
• Failed to maintain a Market Value of Listed Securities of at least $50,000,000 for 30 consecutive trading days.
• Failed to maintain a minimum of 1,100,000 Publicly Held Shares.
• Failed to maintain a Market Value of Publicly Held Shares of at least $15,000,000 for 30 consecutive trading days.
• Nasdaq has halted trading in the company's securities as of July 15, 2025.
• There is no assurance that the Nasdaq Hearings Panel will grant the company's request for continued listing or a stay of the suspension.
• There is no assurance that the company will be able to regain compliance with listing requirements or otherwise satisfy other Nasdaq listing criteria.

Risks

• Risk of delisting from the Nasdaq Global Market if the appeal is unsuccessful or not filed by the deadline.
• Uncertainty regarding the Nasdaq Hearings Panel's decision on the appeal and request for a stay of suspension.
• Failure to consummate the business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. could prevent regaining compliance with listing requirements.
• Potential loss of liquidity and investor confidence due to the trading halt and potential delisting.
• Inability to satisfy other Nasdaq listing criteria even if current non-compliance issues are addressed.

Future Outlook

The company intends to appeal Nasdaq's delisting determination and request a stay of the trading suspension. It is diligently attempting to consummate its previously announced business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. The company believes that it will be in compliance with Nasdaq listing requirements upon the completion of this transaction. However, there is no assurance that the appeal will be granted, the stay will be approved, or that the company will ultimately regain compliance.

Management Comments

• "The Company intends to request a hearing before the panel to appeal the delisting determinations and to request a stay of the suspension of the Companys securities from trading."
• "The Company has been diligently attempting to consummate its previously announced business combination with Shenzhen Qianzhi BioTechnology Co. Ltd."
• "The Company believes that it will be in compliance with the listing requirements upon consummation of such transaction."
• "There can be no assurance that the panel will grant the Companys request for continued listing or a stay of the suspension of the Companys securities."
• "There can be no assurance that the Company will be able to regain compliance with the listing requirements discussed above or otherwise satisfy the other NASDAQ listing criteria."

Industry Context

This event highlights the ongoing challenges faced by some Special Purpose Acquisition Companies (SPACs) in meeting post-listing requirements, particularly concerning shareholder base, market capitalization, and liquidity. Many SPACs struggle to identify and complete suitable business combinations within their mandated timelines, and even after identifying a target, maintaining listing compliance can be difficult if investor interest wanes or the underlying business does not meet market expectations. The application of more stringent criteria by Nasdaq (Rule 5101) underscores a broader regulatory focus on maintaining market integrity and investor protection, especially for companies that fall significantly below minimum thresholds.

Comparison to Industry Standards

• Bowen Acquisition Corp's failure to meet Nasdaq's continued listing standards places it significantly below the operational benchmarks for publicly traded companies on a major exchange.
• The company failed to meet the minimum shareholder count of 400, a basic threshold for public companies.
• The company failed to maintain a Market Value of Listed Securities of at least $50,000,000 over 30 consecutive trading days, a standard measure of a company's market presence and investor confidence.
• The company did not meet the requirement of 1,100,000 publicly held shares, which ensures sufficient liquidity and public float.
• The company also failed to maintain a Market Value of Publicly Held Shares of at least $15,000,000 over 30 consecutive trading days, another key liquidity and market interest benchmark.
• These failures indicate a significant deviation from the expected operational and market engagement standards for a company listed on the Nasdaq Global Market, suggesting a lack of investor interest and/or insufficient public float compared to its peers.

Stakeholder Impact

• Shareholders face significant risk of delisting, loss of liquidity due to the trading halt, and potential loss of investment value. The value of their shares may be severely impacted if the company moves to an over-the-counter market or ceases public trading.
• Potential investors face high risk due to the company's non-compliance and uncertain future listing status, making it an unattractive investment.
• Management and employees may experience impacts on company morale, future operations, and the ability to attract talent if the company is delisted.
• The proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. is at risk if Bowen Acquisition Corp cannot maintain its listing, potentially complicating or derailing the merger.

Next Steps

• Bowen Acquisition Corp intends to request a hearing before a Nasdaq Hearings Panel to appeal the delisting determinations.
• The company plans to request a stay of the suspension of its securities from trading pending the hearing.
• The company is diligently attempting to consummate its previously announced business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.

Key Dates

Recommendation

Keywords

Bowen Acquisition Corp, BOWN, Nasdaq, Delisting, Listing Rules, Trading Halt, SEC Filing, 8-K, Special Purpose Acquisition Company, SPAC, Business Combination, Shenzhen Qianzhi BioTechnology Co. Ltd., Shareholders, Market Value, Publicly Held Shares, Compliance